Related Experiment Video
Updated: May 20, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Clinical trials of small molecule inhibitors in high-grade glioma
1Medical Scientist Training Program, University of Colorado School of Medicine, Aurora, CO80045, USA.
Abstract:
High-grade gliomas are rapidly progressing and generally fatal neoplasms of the brain. Chemotherapy has continued to provide only limited benefit for patients harboring these tumors. The recurrence of common mutations, combined with the similarities of many of the acquired capabilities and characteristics of solid tumors, suggest many common therapeutic targets. During the past few decades, an increased understanding of many of the cellular regulatory mechanisms associated with carcinogenesis has provided an opportunity for the development of pathway-specific small molecule targeted inhibitors (SMIs). This article reviews the use of SMIs in the treatment of high-grade glioma.
Insights
Small molecule inhibitors (SMIs) offer new therapeutic targets for high-grade gliomas, a type of brain cancer. This review explores the potential of SMIs in treating these aggressive tumors.
Area of Science:
- Neuro-oncology
- Molecular biology
- Pharmacology
Background:
- High-grade gliomas are aggressive, fatal brain tumors with limited treatment options.
- Conventional chemotherapy offers minimal benefit for patients with these neoplasms.
- Tumorigenesis involves common mutations and cellular mechanisms, suggesting shared therapeutic targets.
Purpose of the Study:
- To review the application of small molecule inhibitors (SMIs) in treating high-grade gliomas.
- To highlight the potential of targeted therapies in neuro-oncology.
Main Methods:
- Literature review of studies on small molecule inhibitors and high-grade gliomas.
- Analysis of cellular regulatory mechanisms and carcinogenesis pathways relevant to glioma treatment.
- Synthesis of information on the efficacy and development of SMIs for brain tumors.
Main Results:
- Small molecule inhibitors (SMIs) represent a promising class of targeted therapies.
- Understanding of carcinogenesis pathways has enabled the development of pathway-specific inhibitors.
- SMIs offer a potential strategy to overcome limitations of traditional chemotherapy.
Conclusions:
- Small molecule inhibitors (SMIs) are emerging as a significant therapeutic approach for high-grade gliomas.
- Targeted inhibition of specific molecular pathways holds promise for improving patient outcomes.
- Further research and clinical application of SMIs are warranted in neuro-oncology.
